MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.


Journal Article

Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary open-angle glaucoma or ocular hypertension. MK-507 was given every 8 or 12 hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

Full Text

Cited Authors

  • Lippa, EA; Schuman, JS; Higginbotham, EJ; Kass, MA; Weinreb, RN; Skuta, GL; Epstein, DL; Shaw, B; Holder, DJ; Deasy, DA

Published Date

  • March 1, 1991

Published In

Volume / Issue

  • 98 / 3

Start / End Page

  • 308 - 312

PubMed ID

  • 2023750

Pubmed Central ID

  • 2023750

Electronic International Standard Serial Number (EISSN)

  • 1549-4713

International Standard Serial Number (ISSN)

  • 0161-6420

Digital Object Identifier (DOI)

  • 10.1016/s0161-6420(91)32295-4


  • eng